Huadong Pharmaceutical announced that Zhejiang Daoer Biotechnology Co., Ltd., a holding subsidiary of the company, received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and its application for injectable DR30206 clinical trial was approved. This product is a class 1 therapeutic biological product. It is an antibody fusion protein targeting PD-L1, VEGF, and TGF-beta. The approved indication is for use in patients with locally advanced/unresectable non-small cell lung cancer that has not progressed after synchronized/sequential chemotherapy. The product still needs to complete follow-up clinical trials and be approved before it can be marketed. This progress will not have a significant impact on the company's recent performance.

Huadong Pharmaceutical announced that Zhejiang Daoer Biotechnology Co., Ltd., a holding subsidiary of the company, received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and its application for injectable DR30206 clinical trial was approved. This product is a class 1 therapeutic biological product. It is an antibody fusion protein targeting PD-L1, VEGF, and TGF-beta. The approved indication is for use in patients with locally advanced/unresectable non-small cell lung cancer that has not progressed after synchronized/sequential chemotherapy. The product still needs to complete follow-up clinical trials and be approved before it can be marketed. This progress will not have a significant impact on the company's recent performance.